Roivant's mosliciguat shows PVR reduction in phase 2 PH-ILD trial

September 8, 2026 6:01 AM

Roivant Sciences (Nasdaq: ROIV) announced positive results from its Phase 2 PHocus clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found